BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoon JH, Kim SM, Kang G, Kim HJ, Jun CH, Choi SK. A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis. Medicine (Baltimore) 2019;98:e17343. [PMID: 31574875 DOI: 10.1097/MD.0000000000017343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Okubo H, Atsukawa M, Okubo T, Ando H, Nakadera E, Ikejima K, Nagahara A. Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment. Sci Rep 2022;12:7847. [PMID: 35552472 DOI: 10.1038/s41598-022-11707-6] [Reference Citation Analysis]
2 Hara T, Ohara T, Taniguchi M, Sakai H, Oka K, Iwai N, Tsuji T, Okuda T, Nagata A, Komaki T, Sakagami J, Kagawa K. Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection. Intern Med 2021;60:2437-43. [PMID: 33612683 DOI: 10.2169/internalmedicine.6664-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jain A, Mumtaz K. Acute Liver Injury due to Glecaprevir/Pibrentasvir in a Patient with Chronic Hepatitis C Virus Infection without Cirrhosis. Avicenna J Med. [DOI: 10.1055/s-0042-1750716] [Reference Citation Analysis]